Drawing for ONTREZZA

USPTO serial 87372092

ONTREZZA

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
WELLS, KELLEY L
Law office
TTAB

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 604: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with ONTREZZA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Oral, transdermal, injectable and intravaginal contraceptive preparations; Hormone replacement therapy preparations; Pharmaceutical preparations for the prevention of preterm birth or pregnancy; Pharmaceutical preparations for the treatment and prevention of overactive bladder; Pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; Fertility enhancing preparations; Pharmaceuticals and medicines for the treatment and prevention of sexual dysfunction; Pharmaceutical preparations for the treatment and prevention of dermatological diseases and disorders; Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin; Pharmaceutical preparations used in connection with and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; dermatological formulations, namely, medicated cleansers, medicated dry skin lotions, gels and creams, medicated skin lighteners and acne medications; none of the foregoing relating to pharmaceuticals for use in oncologyABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 3, 2018MAB4ABANDONMENT NOTICE MAILED - INTER PARTES DECISION—
Aug 2, 2018ABN4ABANDONMENT - AFTER INTER PARTES DECISION—
Aug 2, 2018OP.TOPPOSITION TERMINATED NO. 999999—
Aug 2, 2018OP.DOPPOSITION DISMISSED NO. 999999—
Mar 21, 2018OP.IOPPOSITION INSTITUTED NO. 999999—
Jan 25, 2018ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Dec 26, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 26, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Dec 6, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Nov 21, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Nov 20, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Nov 20, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Nov 15, 2017ALIEASSIGNED TO LIE—
Nov 3, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 12, 2017GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
May 12, 2017GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
May 12, 2017EPENCOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY—
May 12, 2017CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
May 9, 2017DOCKASSIGNED TO EXAMINER—
Mar 21, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Mar 18, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance